

Massachusetts Division of Health Care Finance and Policy Application for All-Payer Claims Database (APCD) Data

Applications for APCD data must meet the requirements set forth in regulation **114.5 CMR 22.00: Health Care Claims Data Release** and any Administrative Bulletins promulgated under this regulation. The regulation and bulletins are available online at <http://www.mass.gov/chia/gov/hcf/regulations.html>. Information provided on pages 1-4 of this application will be posted on the internet for public comment.

A. APPLICANT INFORMATION	
Applicant Name:	Hermik Babakhanlou-Chase
Title:	Director, Office of Data Analytics and Decision Support
Organization:	Bureau of Substance Abuse Services, MA Department of Public Health
Project Title:	Substance Abuse Treatment Needs and Services Gap Analysis
Date of Application:	September 28, 2012
Brief Description of Project (240 character limit)	<p>The Bureau of Substance Abuse Services has identified and implemented projects related to its Strategic Priorities to address the most critical and crucial aspects of substance abuse treatment and prevention. Strategic Priority #1 focuses on the use of multi-source, multi-agency data to identify both priority population groups and gaps in access to substance abuse services. The All-Payer Claims Database data will provide data that will be utilized to enhance and enrich the data model being developed to achieve this goal:</p> <p style="background-color: yellow;">Identify populations with unmet needs, including populations most severely impacted by substance abuse problems, and populations that are disproportionately underserved by the substance abuse treatment system.</p> <p>The data framework will be many layered and multi-faceted, and the APCD data will provide the opportunity to include outpatient treatment information, data previously unavailable to the BSAS.</p>

B. DATA REQUESTED

1. PUBLIC USE			
File	SINGLE USE* '08 – '09 – '10	REPEATED USE* '08 – '09 – '10	MULTIPLE USE* '08 – '09 – '10
Medical Claims	X X X	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Pharmacy Claims	X X X	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Dental Claims	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Membership Eligibility	X X X	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Provider	X X X	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Product	X X X	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

2. RESTRICTED USE			
File	SINGLE USE*	REPEATED USE*	MULTIPLE USE*

	'08 – '09 – '10	'08 – '09 – '10	'08 – '09 – '10
Medical Claims	X X X	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Pharmacy Claims	X X X	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Dental Claims	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Membership Eligibility	X X X	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Provider	X X X	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Product	X X X	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

See Appendix A for list of Public Data Use Elements

* The Division reserves the right to change proposed “use level” after review of this application.

Definitions:

- **Single Use:** Use of the data for a project or study.
- **Repeated Use:** Use of the data as an input to develop a report or product for sale to multiple clients or customers provided that it will NOT disclose APCD data. Examples include: development of a severity index tool, development of a reference tool used to inform multiple consulting engagements where no APCD data is disclosed.
- **Multiple Use:** Use of the data to develop a product or service that will be sold in the marketplace and will disclose APCD data. Examples include: a benchmark report produced by analyzing APCD data, a query tool to ease access to APDC data.

3. **Filters:** If you are requesting data elements from the Restricted Use dataset, describe any filters you are requesting to use in order to limit your request to the minimum set of records necessary to complete your project. (For example, you may only need individuals whose age is less than 21, claims for hospital services only, or only claims from small group products.)

Records pertaining to behavioral health carve outs will be used in the same manner as the remainder of the APCD data.

File	Data Element(s)	Range of Values Requested
Medical Claims	See Attachment 1	
Pharmacy Claims	See Attachment 1	
Dental Claims	N/A	
Membership Eligibility	See Attachment 1	
Provider	See Attachment 1	
Product	See Attachment 1	

4. **Restricted data elements:** If you are requesting Data Elements from the Restricted Use dataset, list each restricted data element you are requesting on the attached Data Element List and explain why you need access to EACH Restricted Use data element for your project. Limit your request to the minimum data elements necessary to complete the project and be specific as to how each element relates to your proposed model/analytic plan. Add rows to this table as needed.

Please See Appendix A for a more detailed justification for the request for Restricted Data Elements

Restricted Data Element Name	Restricted Data Element Description	Data File (Medical, Pharmacy, Dental, Eligibility, Provider, Product)	Justification (reason this data element is necessary for your project)
PR001	Product ID	Product	Key to member needs dimension
HD002	Payer	Product	Member needs dimension
PR002	Product Name	Product	Member needs dimension
ME012	Individual Relationship Code	Eligibility	Member needs dimension
ME015	Member City Name	Eligibility	Member needs dimension
ME017	Member Zip Code (first 3 digits)	Eligibility	Member needs dimension
ME040	Product ID Number	Eligibility	Key to product
ME046	Member PCP ID	Eligibility	Member needs dimension
ME107	CarrierSpecificUniqueMemberID	Eligibility	Key
MC018	Admission Date	Eligibility	Trend Analysis
MC024	Service Provider Number	Eligibility	Needs dimension
MC059	Date of Service – From	Eligibility	Trend Analysis
MC060	Date of Service – To	Eligibility	Trend Analysis
MC069	Discharge Date	Eligibility	Trend Analysis
MC076	Billing Provider Number	Eligibility	Key
MC112	Referring Provider ID	Eligibility	Needs dimension
MC137	CarrierSpecificUniqueMemberID	Eligibility	Key
PC032	Date Prescription Filled	Pharmacy	Trend Analysis
PC107	CarrierSpecificUniqueMemberID	Pharmacy	Key
PV002	Plan Provider ID	Provider	Key
PV056	Provider Affiliation	Provider	Needs dimension
Derived by DHCFP	Unique Record ID		Key

C. PURPOSE AND INTENDED USE

1. Please describe the purpose of your project and how you will use the APCD.

The Substance Abuse Treatment Needs and Services Gap Analysis project is one of many related efforts geared towards reaching the Bureau's goal of reducing substance abuse and its consequences in the Commonwealth through using state and local data related to substance abuse, its treatment, related morbidity, and other consequences. The project, now underway at the Bureau, is intended to enhance the Bureau's insight into the treatment needs of citizens in the Commonwealth. Focused on identifying the disproportionate use of treatment and the needs of special population groups (such as pregnant women), the project is utilizing census and surveillance data along with administrative treatment data to identify and evaluate gaps in treatment. The integration and use of APCD claims based data (and especially outpatient data, previously not available to BSAS) as part of the project will allow us to further refine our approach to identifying subpopulations in need of treatment, as indicated by substance abuse diagnoses in the claims data.

APCD data will be used to generate aggregate counts of individuals in need (based on diagnosis) for demographic subpopulations across the Commonwealth. These counts will be overlaid on our existing needs-based model to further refine/stratify estimates of need in those demographic subpopulations. In addition, we will create estimates of medically-related treatment cost that can inform potential cost offset opportunities between the substance and medical treatment systems.

2. Please explain why completing your project is in the public interest.

The use of APCD as part of the Substance Abuse Treatment Needs and Services Gap Analysis project will benefit citizens of the Commonwealth as it will further inform initiatives related to SAMHA funding requirements and the BSAS Strategic goals of creating strategies to address disproportionate treatment use and underutilization of services within special populations. The APCD data will allow for the identification, based on medical claim experience, of previously unidentifiable subpopulations in need of treatment as well as the subset of the population receiving outpatient substance abuse treatment services that is not captured in any other administrative data base. Of note, this will include the ability to gain knowledge of co-morbid disease prevalence within subpopulations that will result in better targeting intervention strategies. In addition, the project will enhance service management strategy design using data to identify trends in both overutilization and underutilization of services and potential offsets and cost reduction opportunities between the behavioral and medical treatment systems, thus potentially providing increased and improved services to populations in need without an attendant increase in cost. Finally, the project will provide data analysis and decision support to regulators, providers, and payers related to need for and availability of services, efficacy of interventions,

appropriateness of the level of care provided, and the allocation of treatment funding.

3. **Attach** a brief (1-2 pages) description of your research methodology. (This description will not be posted on the internet.)

See Attachment 2

4. Has your project received approval from your organization's Institutional Review Board (IRB)?

Yes, and a copy of the approval letter is attached to this application

No, the IRB will review the project on _____

No, this project is not subject to IRB review

No, my organization does not have an IRB

D. APPLICANT QUALIFICATIONS

1. Describe your qualifications to perform the research described or accomplish the intended use.

BSAS will leverage the project team, processes and technologies used to design and build the BSAS Performance Management System. The team has experience in both the acquisition and internalization of payer claims data and the use of claims data in the development of analytic models.

Team Members Include

- Hermik Babakhanlou-Chase, M.P.H.: Interim Director, Office of Data Analytics and Decision Support, Bureau of Substance Abuse Services, has several years of experience in research and 10 years of experience as an epidemiologist and data analyst in BSAS.
- Craig Johnson, President and Principal Consultant at Synthesis Health Systems, has expertise in both payer claims data and substance abuse encounter data management; with experience in commercial healthcare predictive modeling companies that rationalize and enrich claims based payer data.
- Adam Pojani, Information Practice Manager at Synthesis Health Systems, has more than ten years experience in healthcare technical operation and data management. He has developed numerous warehousing and business intelligence solutions.
- David Cavanagh, Ph.D., Epidemiologist, Office of Data Analytics and Decision Support, has fifteen years of experience as a data analyst and has considerable expertise in SAS.
- David Hu, M.P.H., Epidemiologist, Office of Data Analytics and Decision Support, has ten years of experience as a data analyst and has considerable expertise in SAS.
- Tina Donnarummo, Senior Business Intelligence Consultant at Synthesis Health Systems, has business intelligence and data warehousing experience, is a Cognos certified engineer, an expert database developer.
- Mary Portais, Senior Healthcare Business Systems Consultant at Synthesis Health Systems has significant experience in project management and business analysis. She has a background in managing cross-functional teams, developing and implementing

policies, and quality assurance.

2. Describe the software you plan to use to analyze the data and the experience that the applicant's team members have in using that software.

BSAS will leverage the technologies used to design and build the BSAS Performance Management System. Built using SQLServer and Cognos, the existing system integrates multi-source data in to a common data warehouse performing data validation/audit to ensure consistency and integrity of the data across sources. Data is enriched with relevant diagnostic/procedure groupings and outcome markers. Finally, a business intelligence or reporting layer in Cognos provides a suite of views and reports for analysis.

Specifically we will utilize the following software:

- SQLServer – database management services.
- SQLServer/SSIS – Data intake, translation and transformation in to our data mart.
- Cognos 8.4 – Business intelligence and reporting.
- SAS 9 – Statistical modeling and analysis.

3. Attach résumés or curriculum vitae of the applicant/principal investigator, key contributors, and of all individuals who will have access to the data. (These attachments will not be posted on the internet.)

See Attachment 3

E. DATA LINKAGE AND FURTHER DATA ABSTRACTION

1. Does your project require linking the APCD to another dataset?
YES NO
2. If yes, will the APCD be linked to other patient level data or with aggregate data (e.g. Census data)?
Patient Level Data Aggregate Data

3. If yes, please identify all linkages proposed and explain the reasons(s) that the linkage is necessary to accomplish the purpose of the project.

4. If yes, specify the specific steps you will take to prevent the identification of individual patients in the linked dataset.

F. RE-RELEASE OF DATA

Applicants must obtain prior approval from the Division to publish reports that use APCD files. Applicants must provide the Division with a copy of any report at least 30 days prior to release to outside parties, including peer review and prepublication analysis by anyone other than the individuals named in this Application. The Division will review the report to ensure that the publication will not permit identification of an individual patient or permit identification of a specific payment by individual payer. The Division may prohibit release of reports that may permit identification of individual patients or specific payment by individual payer.

1. Describe your plans to publish or otherwise disclose any APCD data elements, or any data derived or extracted from such data, in any paper, report, website, statistical tabulation, or similar document.

No current explicit plans for publishing or disclosing any APCD derived information. However, results from the analyses will be used internally to BSAS to inform policy and contracting, may be used to support federal reporting requirements, and may be used to provide State legislators and the administration to better inform policy decisions.

2. Will the results of your analysis be publicly available to any interested party? Will you charge a fee for the reports or analysis? Please describe how an interested party will obtain your analysis and, if applicable, the amount of the fee.

There are no public reports currently planned.

3. Will you use the data for consulting purposes?

YES NO

4. Will you be selling standard report products using the data?

YES NO

5. Will you be selling a software product using the data?

YES NO

6. If you have answered "yes" to questions 3, 4 or 5, please (i) describe the types of products, services or studies; (ii) estimate the number and types of clients for which the data will be used and (iii) describe any rerelease of data by your clients.

G. USE OF AGENTS OR CONTRACTORS

Third-Party Vendors. Provide the following information for all agents and contractors who will work with the APCD data.

Company Name:	Synthesis Health Systems
Contact Person:	Craig Johnson
Title:	President and Principal Consultant
Address:	15 Court Square, Boston, MA
Telephone Number:	781-704-9674
Fax Number:	617-826-0190
E-mail Address:	cjohnson@synthesishs.com
Organization Website:	Synthesishs.com

1. Will the agent/contractor have access to the data at a location other than your location or in an off-site server and/or database?

YES NO

Access to data is provided via secure VPN as provisioned under existing contract by ITD.

2. Describe the tasks and products assigned to this agent or contractor for this project.

- Program Management – the contractor will provide program planning and management of the claims project.
- Methodology Design – working with ODADS staff, the contractor will support the development of appropriate analytic methods to align and analyze the claims data.
- Data Intake/Integration – create and execute the SQL scripts/procedures necessary to internalize the data, rationalize/validate, aggregate and align with existing data.
- Report Development – design and develop a suite of reports in the Cognos environment that will support utilization, cost and related analysis.

3. Describe the qualifications of this agent or contractor to perform such tasks or deliver such products.

Contractor has successfully supported the development of the BSAS Performance Management System providing all of the services identified above. In addition, the contractor has significant experience in claims data management including work for health plans and predictive analytic vendors.

4. Describe your oversight and monitoring of the activity and actions of this agent or subcontractor.

Oversight of the contractor will conform to the existing contract management and day to day oversight provided by BSAS today. Hilary Jacobs (Director, Bureau of Substance Abuse Services) is contract manager. Day to day oversight and monitoring of activities specific to this project will be performed by Hermik Babakhanlou-Chase (Interim Director, Office of Data Analytics and Decision Support).

Attachment 1A

APCD Data Integration into BSAS Needs Assessment Framework

1. BSAS develops a comprehensive list of substance abuse related ICD9 diagnostic codes for use in the data extraction process.
2. The Substance Abuse ICD9 diagnostic code list is distributed to an APCD contact on behalf of BSAS.
3. The APCD contact submits this list to the data repository team for use in their data extraction process.
4. The BSAS APCD data extract process includes several steps.
 - Identify all members, using payer specific unique member identifiers, within the APCD data repository that have had a medical claim with any one of the substance abuse related ICD9 diagnostic codes (See Substance Abuse ICD9 diagnostic code list).
 - Using the distinct list of payer specific unique member identifiers, pull APCD data from the following files.
 - Medical Claims
 - Pharmacy Claims
 - Member Eligibility
 - Product
 - Provider
 - The data extract process will include all data elements within each file that is available to BSAS.
5. The result of this process is a set of inbound matching files including medical claims, pharmacy claims, member eligibility, product, and provider data.
6. Upon receipt of APCD data, it will be integrated into the BSAS needs assessment framework for utilization in developing indices of need.

Attachment 1B: ICD Codes for Filtering

Substance Abuse ICD9 Diagnosis Codes			
icd9_dx	dx_name	dx_category	substance_type
291	Alcohol-induced mental disorders	Alcohol-induced mental disorders	ALCOHOL
2910	Alcohol withdrawal delirium	Alcohol-induced mental disorders	ALCOHOL
2911	Alcohol-induced persisting amnestic disorder	Alcohol-induced mental disorders	ALCOHOL
2912	Alcohol-induced persisting dementia	Alcohol-induced mental disorders	ALCOHOL
2913	Alcohol-induced psychotic disorder with hallucinations	Alcohol-induced mental disorders	ALCOHOL
2914	Idiosyncratic alcohol intoxication	Alcohol-induced mental disorders	ALCOHOL
2915	Alcohol-induced psychotic disorder with delusions	Alcohol-induced mental disorders	ALCOHOL
2918	Other specified alcohol-induced mental disorders	Alcohol-induced mental disorders	ALCOHOL
29181	Alcohol withdrawal	Alcohol-induced mental disorders	ALCOHOL
29182	Alcohol-induced sleep disorder	Alcohol-induced mental disorders	ALCOHOL
29189	Other alcoholic psychosis	Alcohol-induced mental disorders	ALCOHOL
2919	Unspecified alcohol-induced mental disorders	Alcohol-induced mental disorders	ALCOHOL
292	Drug-induced mental disorders	Drug-induced mental disorders	DRUG
2920	Drug withdrawal	Drug-induced mental disorders	DRUG
2921	Drug-induced psychotic disorders	Drug-induced mental disorders	DRUG
29211	Drug-induced psychotic disorder with delusions	Drug-induced mental disorders	DRUG
29212	Drug-induced psychotic disorder with hallucinations	Drug-induced mental disorders	DRUG
2922	Pathological drug intoxication	Drug-induced mental disorders	DRUG
2928	Other specified drug-induced mental disorders	Drug-induced mental disorders	DRUG
29281	Drug-induced persisting delirium	Drug-induced mental disorders	DRUG
29282	Drug-induced persisting dementia	Drug-induced mental disorders	DRUG
29283	Drug-induced persisting amnestic disorder	Drug-induced mental disorders	DRUG
29284	Drug-induced mood disorder	Drug-induced mental disorders	DRUG
29285	Drug-induced sleep disorders	Drug-induced mental disorders	DRUG
29289	Other specified drug-induced mental disorder	Drug-induced mental disorders	DRUG
2929	Unspecified drug-induced psychosis	Drug-induced mental disorders	DRUG
303	Alcohol dependence syndrome	Alcohol dependence syndrome	ALCOHOL
3030	Acute alcoholic intoxication	Alcohol dependence syndrome	ALCOHOL
30300	Acute alcoholic intoxication in alcoholism unspecified drinking behavior	Alcohol dependence syndrome	ALCOHOL
30301	Acute alcoholic intoxication in alcoholism continuous drinking behavior	Alcohol dependence syndrome	ALCOHOL
30302	Acute alcoholic intoxication in alcoholism episodic drinking behavior	Alcohol dependence syndrome	ALCOHOL
30303	Acute alcoholic intoxication in alcoholism in remission	Alcohol dependence syndrome	ALCOHOL
3039	Other and unspecified alcohol dependence	Alcohol dependence syndrome	ALCOHOL
30390	Other and unspecified alcohol dependence unspecified drinking behavior	Alcohol dependence syndrome	ALCOHOL
30391	Other and unspecified alcohol dependence continuous drinking behavior	Alcohol dependence syndrome	ALCOHOL
30392	Other and unspecified alcohol dependence episodic	Alcohol dependence syndrome	ALCOHOL

	drinking behavior		
30393	Other and unspecified alcohol dependence in remission	Alcohol dependence syndrome	ALCOHOL
304	Drug dependence	Drug dependence	DRUG
3040	Opioid type dependence	Drug dependence	DRUG
30400	Opioid type dependence unspecified use	Drug dependence	DRUG
30401	Opioid type dependence continuous use	Drug dependence	DRUG
30402	Opioid type dependence episodic use	Drug dependence	DRUG
30403	Opioid type dependence in remission	Drug dependence	DRUG
3041	Sedative, hypnotic or anxiolytic dependence	Drug dependence	DRUG
30410	Sedative, hypnotic or anxiolytic dependence unspecified use	Drug dependence	DRUG
30411	Sedative, hypnotic or anxiolytic dependence continuous use	Drug dependence	DRUG
30412	Sedative, hypnotic or anxiolytic dependence episodic use	Drug dependence	DRUG
30413	Sedative, hypnotic or anxiolytic dependence in remission	Drug dependence	DRUG
3042	Cocaine dependence	Drug dependence	DRUG
30420	Cocaine dependence unspecified use	Drug dependence	DRUG
30421	Cocaine dependence continuous use	Drug dependence	DRUG
30422	Cocaine dependence episodic use	Drug dependence	DRUG
30423	Cocaine dependence in remission	Drug dependence	DRUG
3043	Cannabis dependence	Drug dependence	DRUG
30430	Cannabis dependence unspecified use	Drug dependence	DRUG
30431	Cannabis dependence continuous use	Drug dependence	DRUG
30432	Cannabis dependence episodic use	Drug dependence	DRUG
30433	Cannabis dependence in remission	Drug dependence	DRUG
3044	Amphetamine and other psychostimulant dependence	Drug dependence	DRUG
30440	Amphetamine and other psychostimulant dependence unspecified use	Drug dependence	DRUG
30441	Amphetamine and other psychostimulant dependence continuous use	Drug dependence	DRUG
30442	Amphetamine and other psychostimulant dependence episodic use	Drug dependence	DRUG
30443	Amphetamine and other psychostimulant dependence in remission	Drug dependence	DRUG
3045	Hallucinogen dependence	Drug dependence	DRUG
30450	Hallucinogen dependence unspecified use	Drug dependence	DRUG
30451	Hallucinogen dependence continuous use	Drug dependence	DRUG
30452	Hallucinogen dependence episodic use	Drug dependence	DRUG
30453	Hallucinogen dependence in remission	Drug dependence	DRUG
3046	Other specified drug dependence	Drug dependence	DRUG
30460	Other specified drug dependence unspecified use	Drug dependence	DRUG
30461	Other specified drug dependence continuous use	Drug dependence	DRUG
30462	Other specified drug dependence episodic use	Drug dependence	DRUG
30463	Other specified drug dependence in remission	Drug dependence	DRUG

3047	Combinations of opioid type drug with any other drug dependence	Drug dependence	DRUG
30470	Combinations of opioid type drug with any other drug dependence unspecified use	Drug dependence	DRUG
30471	Combinations of opioid type drug with any other drug dependence continuous use	Drug dependence	DRUG
30472	Combinations of opioid type drug with any other drug dependence episodic use	Drug dependence	DRUG
30473	Combinations of opioid type drug with any other drug dependence in remission	Drug dependence	DRUG
3048	Combinations of drug dependence excluding opioid type drug	Drug dependence	DRUG
30480	Combinations of drug dependence excluding opioid type drug unspecified use	Drug dependence	DRUG
30481	Combinations of drug dependence excluding opioid type drug continuous use	Drug dependence	DRUG
30482	Combinations of drug dependence excluding opioid type drug episodic use	Drug dependence	DRUG
30483	Combinations of drug dependence excluding opioid type drug in remission	Drug dependence	DRUG
3049	Unspecified drug dependence	Drug dependence	DRUG
30490	Unspecified drug dependence unspecified use	Drug dependence	DRUG
30491	Unspecified drug dependence continuous use	Drug dependence	DRUG
30492	Unspecified drug dependence episodic use	Drug dependence	DRUG
30493	Unspecified drug dependence in remission	Drug dependence	DRUG
3050	Nondependent alcohol abuse	Nondependent alcohol abuse	ALCOHOL
30500	Nondependent alcohol abuse unspecified drinking behavior	Nondependent alcohol abuse	ALCOHOL
30501	Nondependent alcohol abuse continuous drinking behavior	Nondependent alcohol abuse	ALCOHOL
30502	Nondependent alcohol abuse episodic drinking behavior	Nondependent alcohol abuse	ALCOHOL
30503	Nondependent alcohol abuse in remission	Nondependent alcohol abuse	ALCOHOL
3052	Nondependent cannabis abuse	Nondependent abuse of drugs	DRUG
30520	Nondependent cannabis abuse unspecified use	Nondependent abuse of drugs	DRUG
30521	Nondependent cannabis abuse continuous use	Nondependent abuse of drugs	DRUG
30522	Nondependent cannabis abuse episodic use	Nondependent abuse of drugs	DRUG
30523	Nondependent cannabis abuse in remission	Nondependent abuse of drugs	DRUG
3053	Nondependent hallucinogen abuse	Nondependent abuse of drugs	DRUG
30530	Nondependent hallucinogen abuse unspecified use	Nondependent abuse of drugs	DRUG
30531	Nondependent hallucinogen abuse continuous use	Nondependent abuse of drugs	DRUG
30532	Nondependent hallucinogen abuse episodic use	Nondependent abuse of drugs	DRUG
30533	Nondependent hallucinogen abuse in remission	Nondependent abuse of drugs	DRUG
3054	Nondependent barbiturate and similarly acting sedative or hypnotic abuse	Nondependent abuse of drugs	DRUG
30540	Sedative, hypnotic or anxiolytic abuse, unspecified	Nondependent abuse of drugs	DRUG
30541	Sedative, hypnotic or anxiolytic abuse, continuous	Nondependent abuse of drugs	DRUG

30542	Sedative, hypnotic or anxiolytic abuse, episodic	Nondependent abuse of drugs	DRUG
30543	Sedative, hypnotic or anxiolytic abuse, in remission	Nondependent abuse of drugs	DRUG
3055	Nondependent opioid abuse	Nondependent abuse of drugs	DRUG
30550	Nondependent opioid abuse unspecified use	Nondependent abuse of drugs	DRUG
30551	Nondependent opioid abuse continuous use	Nondependent abuse of drugs	DRUG
30552	Nondependent opioid abuse episodic use	Nondependent abuse of drugs	DRUG
30553	Nondependent opioid abuse in remission	Nondependent abuse of drugs	DRUG
3056	Nondependent cocaine abuse	Nondependent abuse of drugs	DRUG
30560	Nondependent cocaine abuse unspecified use	Nondependent abuse of drugs	DRUG
30561	Nondependent cocaine abuse continuous use	Nondependent abuse of drugs	DRUG
30562	Nondependent cocaine abuse episodic use	Nondependent abuse of drugs	DRUG
30563	Nondependent cocaine abuse in remission	Nondependent abuse of drugs	DRUG
3057	Nondependent amphetamine or related acting sympathomimetic abuse	Nondependent abuse of drugs	DRUG
30570	Nondependent amphetamine or related acting sympathomimetic abuse unspecified use	Nondependent abuse of drugs	DRUG
30571	Nondependent amphetamine or related acting sympathomimetic abuse continuous use	Nondependent abuse of drugs	DRUG
30572	Nondependent amphetamine or related acting sympathomimetic abuse episodic use	Nondependent abuse of drugs	DRUG
30573	Nondependent amphetamine or related acting sympathomimetic abuse in remission	Nondependent abuse of drugs	DRUG
3058	Nondependent antidepressant type abuse	Nondependent abuse of drugs	DRUG
30580	Nondependent antidepressant type abuse unspecified use	Nondependent abuse of drugs	DRUG
30581	Nondependent antidepressant type abuse continuous use	Nondependent abuse of drugs	DRUG
30582	Nondependent antidepressant type abuse episodic use	Nondependent abuse of drugs	DRUG
30583	Nondependent antidepressant type abuse in remission	Nondependent abuse of drugs	DRUG
3059	Nondependent other mixed or unspecified drug abuse	Nondependent abuse of drugs	DRUG
30590	Other mixed or unspecified drug abuse unspecified use	Nondependent abuse of drugs	DRUG
30591	Nondependent other mixed or unspecified drug abuse continuous use	Nondependent abuse of drugs	DRUG
30592	Nondependent other mixed or unspecified drug abuse episodic use	Nondependent abuse of drugs	DRUG
30593	Nondependent other mixed or unspecified drug abuse in remission	Nondependent abuse of drugs	DRUG
3575	Alcoholic polyneuropathy	Inflammatory and toxic neuropathy	ALCOHOL
3576	Polyneuropathy due to drugs	Inflammatory and toxic neuropathy	DRUG
4255	Alcoholic cardiomyopathy	Cardiomyopathy	ALCOHOL
5353	Alcoholic gastritis	Gastritis and duodenitis	ALCOHOL
5710	Alcoholic fatty liver	Chronic liver disease and cirrhosis	ALCOHOL
5711	Acute alcoholic hepatitis	Chronic liver disease and cirrhosis	ALCOHOL
5712	Alcoholic cirrhosis of liver	Chronic liver disease and cirrhosis	ALCOHOL
5713	Alcoholic liver damage unspecified	Chronic liver disease and cirrhosis	ALCOHOL

76071	Alcohol affecting fetus or newborn via placenta or breast milk	Noxious influences affecting fetus or newborn via place	ALCOHOL
76072	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Noxious influences affecting fetus or newborn via place	DRUG
76073	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinog	Noxious influences affecting fetus or newborn via place	DRUG
76075	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Noxious influences affecting fetus or newborn via place	DRUG
7795	Drug withdrawal syndrome in newborn	Other and ill-defined conditions originating in the per	DRUG
7903	Excessive blood level of alcohol	Nonspecific findings on examination of blood	ALCOHOL
965	Poisoning by opiates and related narcotics	Poisoning by opiates and related narcotics	DRUG
9650	Poisoning by opiates and related narcotics	Poisoning by opiates and related narcotics	DRUG
96500	Poisoning by opium (alkaloids) unspecified	Poisoning by opiates and related narcotics	DRUG
96501	Poisoning by heroin	Poisoning by opiates and related narcotics	DRUG
96502	Poisoning by methadone	Poisoning by opiates and related narcotics	DRUG
96509	Poisoning by other opiates and related narcotics	Poisoning by opiates and related narcotics	DRUG
967	Poisoning by sedatives and hypnotics	Poisoning by sedatives and hypnotics	DRUG
9670	Poisoning by barbiturates	Poisoning by sedatives and hypnotics	DRUG
9671	Poisoning by chloral hydrate group	Poisoning by sedatives and hypnotics	DRUG
9672	Poisoning by paraldehyde	Poisoning by sedatives and hypnotics	DRUG
9673	Poisoning by bromine compounds	Poisoning by sedatives and hypnotics	DRUG
9674	Poisoning by methaqualone compounds	Poisoning by sedatives and hypnotics	DRUG
9675	Poisoning by glutethimide group substances	Poisoning by sedatives and hypnotics	DRUG
9676	Poisoning by mixed sedatives	Poisoning by sedatives and hypnotics	DRUG
9678	Poisoning by other sedatives and hypnotics	Poisoning by sedatives and hypnotics	DRUG
9679	Poisoning by unspecified sedatives and hypnotics	Poisoning by sedatives and hypnotics	DRUG
9680	Poisoning by central nervous system muscle-tone depressants	Poisoning by other central nervous system depressants a	DRUG
9690	Poisoning by antidepressants	Poisoning by psychotropic agents	DRUG
96900	Poisoning by antidepressant, unspecified	Poisoning by psychotropic agents	DRUG
96901	Poisoning by monoamine oxidase inhibitors	Poisoning by psychotropic agents	DRUG

96902	Poisoning by selective serotonin and norepinephrine reuptake inhibitors	Poisoning by psychotropic agents	DRUG
96903	Poisoning by selective serotonin reuptake inhibitors	Poisoning by psychotropic agents	DRUG
96904	Poisoning by tetracyclic antidepressants	Poisoning by psychotropic agents	DRUG
96905	Poisoning by tricyclic antidepressants	Poisoning by psychotropic agents	DRUG
96909	Poisoning by other antidepressants	Poisoning by psychotropic agents	DRUG
9691	Poisoning by phenothiazine-based tranquilizers	Poisoning by psychotropic agents	DRUG
9692	Poisoning by butyrophenone-based tranquilizers	Poisoning by psychotropic agents	DRUG
9693	Poisoning by other antipsychotics neuroleptics and major tranquilizers	Poisoning by psychotropic agents	DRUG
9694	Poisoning by benzodiazepine-based tranquilizers	Poisoning by psychotropic agents	DRUG
9695	Poisoning by other tranquilizers	Poisoning by psychotropic agents	DRUG
9696	Poisoning by psychodysleptics (hallucinogens)	Poisoning by psychotropic agents	DRUG
9697	Poisoning by psychostimulants	Poisoning by psychotropic agents	DRUG
96970	Poisoning by psychostimulant, unspecified	Poisoning by psychotropic agents	DRUG
96971	Poisoning by caffeine	Poisoning by psychotropic agents	DRUG
96972	Poisoning by amphetamines	Poisoning by psychotropic agents	DRUG
96973	Poisoning by methylphenidate	Poisoning by psychotropic agents	DRUG
96979	Poisoning by other psychostimulants	Poisoning by psychotropic agents	DRUG
9698	Poisoning by other specified psychotropic agents	Poisoning by psychotropic agents	DRUG
9699	Poisoning by unspecified psychotropic agents	Poisoning by psychotropic agents	DRUG
9700	Poisoning by analeptics	Poisoning by central nervous system stimulants	DRUG
9701	Poisoning by opiate antagonists	Poisoning by central nervous system stimulants	DRUG
9708	Poisoning by other specified central nervous system stimulants	Poisoning by central nervous system stimulants	DRUG
9709	Poisoning by unspecified central nervous system stimulant	Poisoning by central nervous system stimulants	DRUG
9800	Toxic effect of ethyl alcohol	Toxic effect of alcohol	ALCOHOL
E8600	Accidental poisoning by alcoholic beverages	Accidental poisoning by alcohol not elsewhere classified	ALCOHOL
E8601	Accidental poisoning by other and unspecified ethyl alcohol and its products	Accidental poisoning by alcohol not elsewhere classified	ALCOHOL

Attachment 2

Methodology

Identifying Underserved Populations and Gaps in Access to Substance Abuse Treatment Services

This effort will support BSAS's strategic plan priority #1 leveraging multiple datasets to identify and address disparities in treatment as well as underserved high priority populations. BSAS has already begun the development of a de-identified multi-layer population need and treatment database intended to support the investigation of these issues. The addition of APCD data is critical to this effort as it fills in considerable gaps in known treatment. Encounter level data submitted today to BSAS only covers a subset of substance abuse treatment services delivered within the Commonwealth. This data (collected thru EIM/ESM) consists of acute treatment, residential, medication assisted treatment and several other levels of care. Even with the integration of these data, there are still significant gaps in known treatment including those paid for by non BSAS entities. At a high level, there are two key components necessary for making a relevant analytic dataset.

- **Align treatment need and treatment received** – BSAS is constructing a multi-layered data population framework founded on census data using demographic characteristics of gender, age, race/ethnicity and city/town of residence. There are three main steps in the construction process
 1. Create an anonymous profile record for every citizen in the State
 2. Overlay several treatment need surveillance datasets on top of those profiles

3. Overlay several treatment level datasets on top of those records with identified need

Overlay multiple datasets - As part of its ongoing performance management initiative, BSAS has integrated DHCFP ED/Inpatient and Vital Registry's mortality data (note that both of these datasets are linked at an individual level to BSAS encounter level data). The APCD data, although de-identified, will help fill in the gaps in treatment data including inpatient and outpatient substance abuse treatment services delivered by providers who do not typically submit encounter level data to BSAS.

Leveraging the multi-layered dataset, our analytic approach will to:

- **Identify underserved high priority populations (e.g. pregnant women)** – Integrated APCD data will be used to generate aggregate counts of individuals in need of treatment and correlate with those who receive treatment for demographic subpopulations across the Commonwealth for the purpose of policy and program recommendations.
- **Identify disparities in treatment** – Integrated APCD data will be used to evaluate the relative proportion of individuals treated for substance abuse versus those in need across all demographic subpopulations.
- This is not intended to be a research initiative rather an operation improvement opportunity for changing resource allocation mechanisms and introducing cost savings across the Commonwealth.

Appendix A

Data Elements For Public Release

Product File			
Element	Data Element Name	Masked	Check To
PR006	Product Benefit Type		
PR008	Risk Type		
PR011	Product Active Flag		
PR012	Annual Per Person Deductible Code		
PR013	Annual Per Family Deductible Code		
PR014	Coordinated Care model		
PR899	Record Type		
HD002 / PR001	Payer / Product ID	Masked	
Derived by DHCFP	Unique Record ID		
Member Eligibility File			
Element	Data Element Name	Masked	
ME003	Insurance Type Code/Product		
ME007	Coverage Level Code		
ME013	Member Gender		X
ME014	Member Birth Year		X
ME016	Member State or Province		X
ME018	Medical Coverage		X
ME019	Prescription Drug Coverage		X
ME020	Dental Coverage		X
ME021	Race 1		X
ME022	Race 2		X
ME023	Other Race		X
ME024	Hispanic Indicator		X
ME025	Ethnicity 1		X
ME026	Ethnicity 2		X
ME027	Other Ethnicity		X
ME028	Primary Insurance Indicator		X
ME029	Coverage Type		
ME030	Market Category Code		
ME033	Member language preference		
ME034	Member language preference -Other		
ME035	Health Care Home Assigned Flag		
ME037	Health Care Home Tax ID Number	Masked	
ME038	Health Care Home National Provider ID	Masked	
ME039	Health Care Home Name	Masked	
ME047	Member PCP Effective Date		
ME048	Member PCP Termination Date		
ME049	Member Deductible		
ME050	Member Deductible Used		

Data Elements For Public Release

ME051	Behavioral Health Benefit Flag		X
ME052	Laboratory Benefit Flag		
ME053	Disease Management Enrollee Flag		X
ME059	Disability Indicator Flag		X
ME061	Student Status		
ME062	Marital Status		
ME063	Benefit Status		
ME064	Employee Type		
ME066	COBRA Status		
ME073	Fully insured member		
ME074	Interpreter		
ME077	Members SIC Code	Masked	
ME081	Medicare Code		
ME109	Subscriber State or Province		
ME111	Medical Deductible		
ME112	Pharmacy Deductible		
ME113	Medical and Pharmacy Deductible		
ME114	Behavioral Health Deductible		
ME115	Dental Deductible		
ME116	Vision Deductible		
ME118	Vision Benefit		
ME899	Record Type		
ME001 / ME036	Health Care Home Number	Masked	
ME001 / ME040	Product ID Number	Masked	X
ME001 / ME107	Payer / CarrierSpecificUniqueMemberID	Masked	X
ME001 / ME117	Payer / CarrierSpecificUniqueSubscriberID	Masked	X
Derived by DHCFP	Unique Record ID		X
Medical Claims File			
Element	Data Element Name	Masked	
MC005	Line Counter		X
MC005A	Version Number		
MC012	Member Gender		
MC013	Member Birth Year		
MC015	Member State or Province		
MC020	Admission Type		X
MC021	Admission Source		X
MC023	Discharge Status		X
MC026	National Service Provider ID	Masked	X
MC027	Service Provider Entity Type Qualifier		
MC028	Service Provider First Name		X
MC029	Service Provider Middle Name		X
MC030	Servicing Provider Last Name or Organization Name		X
MC031	Service Provider Suffix		X

Data Elements For Public Release

MC032	Service Provider Specialty		X
MC033	Service Provider City Name		X
MC034	Service Provider State		X
MC035	Service Provider ZIP Code		X
MC036	Type of Bill - on Facility Claims		X
MC037	Site of Service - on NSF/CMS 1500 Claims		X
MC038	Claim Status		X
MC039	Admitting Diagnosis		X
MC040	E-Code		X
MC041	Principal Diagnosis		X
MC042	Other Diagnosis - 1		X
MC043	Other Diagnosis - 2		X
MC044	Other Diagnosis - 3		X
MC045	Other Diagnosis - 4		X
MC046	Other Diagnosis - 5		X
MC047	Other Diagnosis - 6		X
MC048	Other Diagnosis - 7		X
MC049	Other Diagnosis - 8		X
MC050	Other Diagnosis - 9		X
MC051	Other Diagnosis - 10		X
MC052	Other Diagnosis - 11		X
MC053	Other Diagnosis - 12		X
MC054	Revenue Code		X
MC055	Procedure Code		X
MC056	Procedure Modifier - 1		X
MC057	Procedure Modifier - 2		X
MC058	ICD9-CM Procedure Code		X
MC061	Quantity		
MC062	Charge Amount		X
MC063	Paid Amount		X
MC064	Prepaid Amount		
MC065	Copay Amount		
MC066	Coinsurance Amount		
MC067	Deductible Amount		
MC070	Service Provider Country Code		
MC071	DRG		X
MC072	DRG Version		X
MC073	APC		X
MC074	APC Version		X
MC075	Drug Code		X
MC077	National Billing Provider ID	Masked	X
MC078	Billing Provider Last Name or Organization Name		X
MC081	Capitated Encounter Flag		

Data Elements For Public Release

MC083	Other ICD-9-CM Procedure Code - 1		X
MC084	Other ICD-9-CM Procedure Code - 2		X
MC085	Other ICD-9-CM Procedure Code - 3		X
MC086	Other ICD-9-CM Procedure Code - 4		X
MC087	Other ICD-9-CM Procedure Code - 5		X
MC088	Other ICD-9-CM Procedure Code - 6		X
MC089	Paid Date		X
MC090	LOINC Code		
MC092	Covered Days		
MC093	Non Covered Days		
MC094	Type of Claim		X
MC095	Coordination of Benefits/TPL Liability Amount		
MC096	Other Insurance Paid Amount		
MC097	Medicare Paid Amount		X
MC099	Non-Covered Amount		
MC108	Procedure Modifier - 3		X
MC109	Procedure Modifier - 4		X
MC111	Diagnostic Pointer		
MC113	Payment Arrangement Type		
MC114	Excluded Expenses		
MC115	Medicare Indicator		X
MC116	Withhold Amount		
MC117	Authorization Needed		
MC118	Referral Indicator		
MC119	PCP Indicator		
MC120	DRG Level		
MC122	Global Payment Flag		
MC123	Denied Flag		
MC126	Accident Indicator		
MC127	Family Planning Indicator		
MC128	Employment Related Indicator		
MC129	EPSDT Indicator		
MC130	Procedure Code Type		
MC131	InNetwork Indicator		
MC132	Service Class		
MC136	Discharge Diagnosis		X
MC138	Claim Line Type		
MC899	Record Type		
MC001 / MC024	Payer / Service Provider Number	Masked	X
MC001 / MC032	Payer / Service Provider Specialty	Masked	X
MC001 / MC076	Payer / Billing Provider Number	Masked	X
MC001 / MC079	Payer / Product ID Number	Masked	X
MC001 / MC100	Payer / Delegated Benefit Administrator Organization	Masked	

Data Elements For Public Release

MC001 / MC112	Payer / Referring Provider ID	Masked	X
MC001 / MC125	Payer / Attending Provider	Masked	X
MC001 / MC132	Payer / Service Class	Masked	
MC001 / MC134	Payer / Plan Rendering Provider Identifier	Masked	
MC001 / MC135	Payer / Provider Location	Masked	X
MC001 / MC137	Payer / CarrierSpecificUniqueMemberID	Masked	X
MC001 / MC141	Payer / CarrierSpecificUniqueSubscriberID	Masked	X
Derived by DHCFP	Unique Record ID		X
Derived by DHCFP	Final Version Flag		
Pharmacy Claims File			
Element	Data Element Name	Masked	
PC005	Line Counter		X
PC005A	Version Number		
PC012	Member Gender		
PC013	Member Birth Year		
PC015	Member State		
PC020	Pharmacy Name		
PC021	National Pharmacy ID Number	Masked	
PC022	Pharmacy Location City		
PC023	Pharmacy Location State		
PC024	Pharmacy ZIP Code		
PC024A	Pharmacy Country Code		
PC025	Claim Status		
PC026	Drug Code		X
PC027	Drug Name		X
PC028	New Prescription or Refill		
PC029	Generic Drug Indicator		
PC030	Dispense as Written Code		
PC031	Compound Drug Indicator		
PC033	Quantity Dispensed		
PC034	Days Supply		
PC035	Charge Amount		
PC036	Paid Amount		X
PC037	Ingredient Cost/List Price		
PC038	Postage Amount Claimed		
PC039	Dispensing Fee		
PC040	Copay Amount		
PC041	Coinsurance Amount		
PC042	Deductible Amount		
PC044	Prescribing Physician First Name		
PC045	Prescribing Physician Middle Name		
PC046	Prescribing Physician Last Name		
PC048	Prescribing Physician NPI	Masked	

Data Elements For Public Release

PC049	Prescribing Physician Plan Number	Masked	
PC050	Prescribing Physician License Number	Masked	
PC053	Prescribing Physician City		
PC054	Prescribing Physician State		
PC055	Prescribing Physician Zip		
PC057	Mail Order pharmacy		
PC060	Single/Multiple Source Indicator		
PC063	Paid Date		
PC066	Other Insurance Paid Amount		
PC069	Member Self Pay Amount		
PC070	Rebate Indicator		
PC071	State Sales Tax		
PC073	Formulary Code		
PC074	Route of Administration		
PC075	Drug Unit of Measure		
PC110	Claim Line Type		
PC899	Record Type		
PC001 / PC018	Payer / Pharmacy Number	Masked	
PC001 / PC043	Payer / Prescribing ProviderID	Masked	X
PC001 / PC056	Payer / Product ID Number	Masked	X
PC001 / PC059	Payer / Recipient PCP ID	Masked	X
PC001 / PC072	Payer / Delegated Benefit Administrator Organization	Masked	
PC001 / PC107	Payer / CarrierSpecificUniqueMemberID	Masked	
PC001 / PC108	Payer / CarrierSpecificUniqueSubscriberID	Masked	
Derived by DHCFP	Final Version Flag		
Derived by DHCFP	Unique Record ID		
Provider File			
Element	Data Element Name	Masked	
PV006	License Id	Masked	
PV008	Last Name		X
PV009	First Name		X
PV010	Middle Initial		
PV011	Suffix		X
PV012	Entity Name		X
PV013	Entity Code		X
PV014	Gender Code		
PV018	City Name		X
PV019	State Code		X
PV020	Country Code		
PV021	Zip Code		X
PV022	Taxonomy		
PV023	Mailing Street Address1 Name		

Data Elements For Public Release

PV024	Mailing Street Address2 Name		
PV025	Mailing City Name		
PV026	Mailing State Code		
PV027	Mailing Country Code		
PV028	Mailing Zip Code		
PV029	Provider Type Code		X
PV030	Primary Specialty Code		X
PV034	ProviderIDCode		
PV037	Begin Date		
PV038	End Date		
PV039	National Provider ID	Masked	X
PV040	National Provider2 ID	Masked	
PV042	Secondary Specialty2 Code		
PV043	Secondary Specialty3 Code		
PV044	Secondary Specialty4 Code		
PV045	P4PFlag		
PV046	NonClaimsFlag		
PV047	Uses Electronic Medical Records		
PV048	EMR Vendor		
PV049	Accepting New Patients		
PV050	Offers e-Visits		
PV052	Has multiple offices		
PV055	PCP Flag		X
PV057	Provider Telephone		
PV058	Delegated Provider Record Flag		
PV060	Office Type		
PV061	Prescribing Provider		
PV062	Provider Affiliation Start Date		
PV063	Provider Affiliation End Date		
PV064	PPO Indicator		
PV899	Record Type		
PV001 / PV002	Payer/Plan Provider ID	Masked	
PV001 / PV029	Payer/Provider Type Code	Masked	
PV001 / PV030	Payer/Primary Specialty Code	Masked	
PV001 / PV042	Payer/Secondary Specialty2 Code	Masked	
PV001 / PV043	Payer/Secondary Specialty3 Code	Masked	
PV001 / PV044	Payer/Secondary Specialty4 Code	Masked	
PV001 / PV054	Payer/Medical/Healthcare Home ID	Masked	
PV001 / PV056	Payer/Provider Affiliation	Masked	
Derived by DHCFP	Unique Record ID		

Restricted Data Elements

Restricted Data Element Name	Restricted Data Element Description	Data File	Justification (reason this data element is necessary for your project)
PR001	Product ID	Product	Allows us to link to the product name when reporting information on health insurance plans, including determining which products under specific payers perform better and result in better outcomes
HD002	Payer	Product	Health plan coverage is an important factor used in analyzing substance abuse treatment. We plan to report on utilization by health plan payer.
PR002	Product Name	Product	Allows us to identify the name of the product when reporting information on health insurance plans to assess variations in treatment utilization and outcomes by product types under different payment systems.
ME012	Individual Relationship Code	Eligibility	This allows us to see whether the individuals being treated for substance abuse are subscribers or dependents to subscribers.
ME015	Member City Name	Eligibility	This allows us to determine the geographic distribution of treatment and possibly better estimate treatment need by city/town.
ME017	Member Zip Code (first 3 digits)	Eligibility	This allows us to determine the geographic distribution (at a more aggregate level) of treatment and possibly better estimate treatment need by city/town.
ME040	Product ID Number	Eligibility	Allows us to link to product name that will allow us to identify how treatment is distributed across various products/product types.
ME046	Member PCP ID	Eligibility	Allows us to link to the provider name so that we can report on treatment services to patients within PCP aggregations.
ME107	CarrierSpecific UniqueMemberID	Eligibility	This allows us to report on the distinct number of people who utilize various categories of treatment services and correlate to the number who have had substance abuse treatment.
MC018	Admission Date	Eligibility	This allows us to determine the count and percentages of people who have received inpatient medical and substance abuse

			treatment services during a time period.
MC024	Service Provider Number	Eligibility	This allows us to see which health care providers types and affiliations provide the highest/lowest level of substance abuse treatment services.
MC059	Date of Service – From	Eligibility	This allows us to determine the count and percentages of people during a time period who have received outpatient medical and substance abuse treatment services.
MC060	Date of Service – To	Eligibility	This allows us to determine the count and percentages of people during a time period who have received outpatient medical and substance abuse treatment services.
MC069	Discharge Date	Eligibility	This allows us to determine the count and percentages of people during a time period who have received inpatient medical and substance abuse treatment services.
MC076	Billing Provider Number	Eligibility	This allows us to report on the count and percentage of substance abuse treatment delivered to billing providers to better understand where treatment services are being delivered by type of billing provider.
MC112	Referring Provider ID	Eligibility	This allows us to report on the count and percentage of substance abuse treatment referrals made by referring providers.
MC137	CarrierSpecific UniqueMemberID	Eligibility	This allows us to report on the distinct number of people who utilize various categories of treatment services and correlate to the number who have had substance abuse treatment.
PC032	Date Prescription Filled	Pharmacy	Allows us to be able to report on the count and percentage of prescriptions filled within specific periods of time.
PC107	CarrierSpecific UniqueMemberID	Pharmacy	This allows us to report on the distinct number of people who utilize various categories of treatment services and correlate to the number who have had substance abuse treatment.
PV002	Plan Provider ID	Provider	This allows us to link medical and pharmacy claim provider identifiers to provider name for reporting.
PV056	Provider Affiliation	Provider	This allows us to report on the affiliated provider organization to the treating provider.
Derived by DHCFP	Unique Record ID		This allows us to have an internal unique record identifier for control purposes.